Literature DB >> 16089130

[Current status and development of monitoring on adverse reaction of traditional Chinese medicine in China].

Li Zhang1, Xiao-hui Yang, Li-ya Cao, Shaoliang Ji.   

Abstract

With the wide usage of traditional Chinese medicine (TCM) and the diversity of its dosage-forms, the reports about adverse reaction (ADR) caused by TCM were gradually increased. As the cradle of TCM with tremendous manufacturing enterprise engaged for this purpose, to establish and perfect the TCM ADR monitoring is the problem that TCM industry should face to. In this paper, the key point of TCM ADR monitoring was made clear by analysing the current situation and the problems presented in TCM ADR monitoring in China, and indicated that the nowday developing goals of TCM ADR monitoring are to establish and perfect the technologic system for TCM ADR monitoring, strengthen the related basic research and enhance international communication and cooperation in this field.

Mesh:

Substances:

Year:  2005        PMID: 16089130

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  3 in total

1.  Pharmacovigilance in China: current situation, successes and challenges.

Authors:  Li Zhang; Lisa Y L Wong; Ying He; Ian C K Wong
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

2.  Safety evaluation of chinese medicine injections with a cell imaging-based multiparametric assay revealed a critical involvement of mitochondrial function in hepatotoxicity.

Authors:  Meng Wang; Chen-Xiang Liu; Ran-Ran Dong; Shuang He; Ting-Ting Liu; Tie-Chan Zhao; Zhi-Long Wang; Xi-Ya Shen; Bo-Li Zhang; Xiu-Mei Gao; Yan Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-22       Impact factor: 2.629

3.  Spontaneous reporting of adverse drug reactions through electronic submission from regional society healthcare professionals in Korea.

Authors:  Jae-Hyun Lee; Kyung Hee Park; Hyun Joo Moon; Yong Won Lee; Jung-Won Park; Chein-Soo Hong
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.